Detection of tryptase in cytoplasmic granules of basophils in patients with chronic myeloid leukemia and other myeloid neoplasms


Tryptases are serine proteases primarily expressed in mast cells. Normal blood basophils express only trace amounts of the enzyme. However, recent immunohistochemical studies have raised the possibility that neoplastic basophils express significant amounts of tryptase. In this study, tryptase expression was analyzed in normal and neoplastic basophils by immunoelectron microscopy using antitryptase monoclonal antibody G3. Basophils were obtained from patients with chronic myeloid leukemia (CML), idiopathic myelofibrosis (IMF), and myelodysplastic syndrome (MDS), and from healthy donors. Tryptase-immunoreactive material was detected in cytoplasmic granules of basophils in CML, IMF, and MDS. By contrast, normal basophils did not contain significant amounts of tryptase by immunoelectron microscopy. As assessed by reverse transcription-polymerase chain reaction, neoplastic basophils contained messenger RNA (mRNA) for α-trypatase, but no β-trypatase mRNA.

In summary, these data provide evidence that neoplastic basophils in CML, IMF, and MDS can express detectable amounts of tryptase. Therefore, tryptase should not be regarded as specific for mast cells when neoplastic myeloid cells are analyzed. (Blood. 2001;98:2580-2583)
resin-embedded sections as described previously using antitryptase monoclonal antibody G3 (Chemicon, Temecula, CA). After incubation with G3 (4 hours), grids were washed and incubated with goat antimouse antibody conjugated with 10 nM gold particles. Sections were contrasted in uranyl acetate and lead citrate.

Reverse transcription–polymerase chain reaction

Total RNA was extracted from PB-MNCs (CML, n = 2; IMF, n = 1) and reverse-transcribed into complementary DNA (cDNA) as described. The cDNA aliquots (6 μL) were used for polymerase chain reaction (PCR) amplification in 50 μL volume containing PCR buffer, 1.25 U Taq polymerase, 25 μM of upstream and downstream primers (MWG Biotech, Ebersberg, Germany) specific for tryptase (5′ primer: 5′ GAGGCCCCCAG-GAGCAAGTG 3′; 3′ primer: 5′ ACATGCCCCAGCCAGTGAC 3′) or β-actin. Primers were selected to be complementary to identical regions in α- and β-tryptase cDNAs and to display restriction site differences (only β-tryptase–specific PCR products contained a DraIII restriction site). Samples were amplified in 32 cycles at 94°C (1 minute), annealing for 1 minute (63°C), and extension at 72°C (1 minute) after initial denaturation (95°C, 2 minutes). PCR products were subjected to restriction fragment length polymorphism using endonuclease DraIII (Boehringer Mannheim, Mannheim, Germany).

Results and discussion

Detection of tryptase in neoplastic basophils

Basophils from 2 patients with CML, 1 with IMF, and 1 with MDS were examined by electron microscopy. In all samples, basophils were easily identified as round cells containing cytoplasmic granules including so-called particulate granules. In immature basophils nuclei appeared to be round or bilobed. Mature basophils showed segmented nuclei. As assessed by immunoelectron microscopy, a proportion of neoplastic basophils (10%-50%) contained tryptase in their cytoplasmic granules (Figure 1). However, not all granules in a given cell appeared to be labeled. Also, the intensity of labeling in

Figure 1. Tryptase immunoelectron microscopy.

(A) Blood basophil from a patient with chronic phase CML. Tryptase-immunoreactive material is localized to a subset of granules (arrows; original magnification ×5000; inset, ×10 000). (B) Basophil of a healthy donor shows no tryptase expression by immunoelectron microscopy (original magnification ×6500; inset ×13 000). (C) Tryptase immunoelectron microscopy of a CB culture–derived basophil (IL-3, day 13); no significant amounts of tryptase could be detected (original magnification ×4000). (D) Tryptase immunoelectron microscopy of a CB culture–derived MC (SCF, day 28). In this cell tryptase-reactive material could be detected. Note surface projections and granular staining pattern (original magnification ×12 500). 1 bar = 1 μm.
the MDS group and IMF group the levels of tryptase per basophil varied greatly from donor to donor. In basophils from healthy donors (n = 3) granules appeared to be tryptase negative.

Evaluation of tryptase expression in cultured cells

As assessed by immunoelectron microscopy, isolated CD34+ CB-MNCs (blasts, day 0) were tryptase negative. At all times investigated (days 13, 21, 28), SCF-cultured MCs expressed tryptase in their granules, whereas cultured basophils (day 13) did not contain significant amounts of tryptase (Figure 1).

Measurement of cellular tryptase

As assessed by FIA, the levels of total tryptase (β-tryptase + α-protryptase) in basophils (pg/cell) were significantly higher in CML (median: 0.09 pg/cell; mean ± SD = 0.11 ± 0.09) compared with healthy controls (median: 0.03; mean ± SD = 0.03 ± 0.02; P < .05). A higher median tryptase level in basophils was also recorded in MDS, but not in IMF (Table 1).

Tryptase messenger RNA expression

A PCR product of 383 base pairs was generated from cDNA obtained from PB-MNCs of patients with CML (n = 2) and IMF (n = 1). Restriction enzyme digestion (DraIII) resulted in partial degradation of PCR products in a mast cell line (HMC-1) indicating expression of both α- and β-tryptase messenger RNA (mRNA). By contrast, no digestion occurred with the patients’ PCR products, suggesting that basophils contained only α-tryptase mRNA, but not β-tryptase mRNA.

Interpretation of data

Recent observations have raised the possibility that in contrast to normal basophils, immature neoplastic basophils can express significant amounts of tryptase.17-19 Notably, in patients with CML, immature “basophilike” cells were found to react with antitryptase monoclonal antibody.19 However, it could not be clarified whether the labeled cells were indeed basophils or MC-lineage cells. Our immunoelectron microscopy experiments clearly show that tryptase is expressed in the granule compartment of basophils in patients with CML, MDS, and IMF. By contrast, no significant amounts of tryptase were detected in normal basophils.

Interestingly, the so-called particulate granules contained tryptase-immunoreactive material. This granule type is a typical ultrastructural feature of basophils.23-7 However, there was a significant variability in expression of granular tryptase when basophils from different donors were compared. These observations suggest that tryptase production, release, or degradation in basophils varies among donors.

Two types of tryptases, α and β types, have been identified and cloned.15,16 In the present study, the α type of tryptase was found to be the predominant type expressed in neoplastic basophils at the mRNA level. The abnormal expression of α-tryptase gene products in basophils in myeloid malignancies may have several explanations. One could be that the transformation of myeloid progenitors is associated with increased enzyme production. The possibility that tryptase is selectively expressed at a certain (immature) stage of basophil maturation seems unlikely; in fact, cultured immature basophils did not express substantial amounts of tryptase.

So far, tryptase has been widely used as a specific marker to identify MCs in patients with mastocytosis and other hematologic disorders.20 The results of our study suggest that in various myeloid neoplasms, tryptase may also be detectable in basophils. Therefore, tryptase should not be regarded as MC specific in such patients. Whether basophil tryptase can be used as a marker to monitor patients with CML or other myeloid neoplasms is currently under investigation.

References

1. Galli SJ. Biology of disease: new insights into “the riddle of the mast cells”: microenvironmen-
7. Dvorak AM, Dvorak HF, Galli SJ. Ultrastructural criteria for identification of mast cells and ba-

Table 1. Patient characteristics and results

<table>
<thead>
<tr>
<th>Variable</th>
<th>CML*</th>
<th>MDS*</th>
<th>IMF*</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>6</td>
<td>3</td>
<td>8</td>
<td>12</td>
</tr>
<tr>
<td>Age (median)</td>
<td>53</td>
<td>80</td>
<td>78</td>
<td>26</td>
</tr>
<tr>
<td>WBC/μL (median)</td>
<td>24000</td>
<td>5810</td>
<td>8440</td>
<td>ND</td>
</tr>
<tr>
<td>Hemoglobin, g/dL (median)</td>
<td>12.8</td>
<td>8.2</td>
<td>10.1</td>
<td>ND</td>
</tr>
<tr>
<td>Percent blood basophils (median)</td>
<td>4</td>
<td>3</td>
<td>3</td>
<td>ND</td>
</tr>
<tr>
<td>Percent basophils in MNCs (median)</td>
<td>7</td>
<td>4.6</td>
<td>4</td>
<td>3.3</td>
</tr>
<tr>
<td>Tryptase, pg/basophil (median)</td>
<td>0.09+</td>
<td>0.55</td>
<td>0.01</td>
<td>0.03†</td>
</tr>
</tbody>
</table>

†As assessed by Mann-Whitney U test, the median tryptase levels in basophils were significantly higher in CML patients compared to the control group (P < .05). In the MDS group and IMF group the levels of tryptase per basophil varied greatly from donor to donor, and overall no significant difference from the control group was found (P > .05).

* A subset of patients was treated with cytoreductive drugs. In CML, 3 patients were untreated, 1 received hydroxyurea, and 2 a combination of hydroxyurea and interferon-α. Of the MDS patients, 1 received hydroxyurea, and 2 were untreated. In the IMF group, 3 patients received hydroxyurea and 1 interferon-α; the remaining patients were not treated.

12. Dvorak AM, Mitsui H, Ishizaka T, Human and mu-
rine recombinant c-kit ligands support the devel-
15. Miller JS, Westin EH, Schwartz LB. Cloning and characterization of complementary DNA for hu-
16. Miller JS, Moxley G, Schwartz LB. Cloning and character-